GEN Exclusives

More »

GEN News Highlights

More »
Aug 29, 2007

Catalent Signs Deal with ALK-Abello to Expand Zydis Production Capacity

  • Catalent Pharma Solutions and ALK-Abello are collaborating to increase Zydis® oral dissolving tablet production capacity dedicated to ALK-Abello’s immunotherapy products.

    ALK-Abello will fund a new production line for current and future tablet-based allergy products, which will be located at Catalent’s Swindon, U.K. facility. The companies expect to begin production on the new line in 2010.

    ALK-Abello launched Grazax®, a tablet-based vaccine against grass pollen allergy, using Catalent’s Zydis oral dissolving tablet technology. Catalent is already producing the Zydis formulation of Grazax in the Swindon facility.

    “We are pleased to have reached this next important step in our relationship with ALK-Abello, which began more than four years ago,” comments Thomas Stuart, group president of Oral Technologies for Catalent. “The clinical success of Grazax demonstrates that protein-based products such as allergens can be taken orally by patients rather than via injection, and we believe Zydis provides unique advantages to deliver these and other types of novel compounds.”


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

GEN Poll

More » Poll Results »

Secure Science

Should bans on science education, of the sort imposed on Iranians hoping to study physics and engineering in the United States, encompass other nationals and other fields of study, including biotechnology?